Alerta De Seguridad para Xpert BCR-ABL Monitor Technical Name: Chromosome Translocation BCR-ABL Registration Number ANVISA: 81062710016 Hazard Class: III Affected Model: Kit with 10 tests (cartridges with integrated reaction tubes) Serial numbers affected: LOT: 1000041807

Según Agência Nacional de Vigilância Sanitária (ANVISA), este evento ( alerta de seguridad ) involucró a un dispositivo médico en Brazil que fue producido por CEPHEID BRASIL IMPORTAÇÃO, EXPORTAÇÃO E COMÉRCIO DE PRODUTOS DE DIGANÓSTICOS LTDA.; CEPHEID.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • ID del evento
    2311
  • Fecha
    2017-06-13
  • País del evento
  • Fuente del evento
    ANVISA
  • URL de la fuente del evento
  • Notas / Alertas
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notas adicionales en la data
    The proposed action to address device failures is to send customers a Field Security Notification (FSN), which informs customers to stop using the BCR-ABL Monitor product, lot 1000041807, which will later be collected by the company.
  • Causa
    A new test method for bcr-abl monitor shows that performance deteriorates after 12 months when stored at 2-28 ° c. the d10939 rev k stability report reduces the stability validity from 24 months to 12 months for the xpert bcr-abl monitor products. analysis of the mode of failure of bcr-abl in relation to the impact of the product result on the patient: stability data from the assay beyond 13 months sub-reported the amount of bcr-abl mrna transcript at the lowest level tested, 1%. the reported performance of the xpert bcr-abl monitor assay allows a 2-fold variance in the ratio of bcr-abl mrna transcripts to abl, considering that at 25 months, we observed a 3-fold difference. at 13 months, a variance of 1.8 times was observed, which is within the variability of performance of the declared product. although beyond the stability limits, the detected level of transcription of bcr-abl mrna is correctly termed as the bcr-abl detected.
  • Acción
    Field Action Code CPHD-002/2017 triggered under the responsibility of the company Olympus Optical do Brasil Ltda. Company will collect for further destruction of the product.